Main Uses of Crestor

Crestor, which contains the active substance rosuvastatin, belongs to a group of medications known as statins. It is primarily used to manage lipid levels in the blood and to reduce the risk of cardiovascular events.

Management of High Cholesterol

The medication is used to treat high cholesterol levels in patients who have been diagnosed with primary hypercholesterolaemia or mixed dyslipidaemia. It works by reducing the amount of "bad" cholesterol (low-density lipoprotein or LDL) and triglycerides produced by the liver, while simultaneously increasing the levels of "good" cholesterol (high-density lipoprotein or HDL).

Prevention of Cardiovascular Disease

Crestor is indicated for individuals who are at a high risk of a first heart attack, stroke, or related heart complications. This includes patients with existing risk factors such as high blood pressure, diabetes, or a family history of heart disease, even if their cholesterol levels are currently within a normal range.

Therapeutic Benefits

Reduction of Plaque Buildup

By lowering LDL cholesterol, the medication helps slow the progression of atherosclerosis, a condition where fatty deposits (plaque) build up on the inner walls of the arteries. This helps maintain clearer blood vessels and improves overall blood flow.

Long-term Health Outcomes

The primary benefit of treatment is the significant reduction in the statistical likelihood of serious cardiovascular incidents. Regular use, in conjunction with appropriate lifestyle modifications, contributes to better long-term management of heart health and vascular integrity.

Regulatory References

1. NIH MedlinePlus overview of Rosuvastatin

Who Can and Cannot Use Crestor (Rosuvastatin)?

The eligibility for using Crestor is strictly governed by regulatory classifications based on physiological status, age, and pre-existing medical conditions.

Populations Who Must Not Use (Contraindicated)

Crestor is absolutely contraindicated in the following groups, as stated in official regulatory labeling:

• Active Liver Disease: Patients with active liver disease, including unexplained, persistent elevations of liver enzymes.
• Pregnancy and Lactation: Women who are pregnant or may become pregnant, and women who are breastfeeding.
• Myopathy: Individuals with pre-existing myopathy or conditions that increase the risk of muscle damage.

Eligibility and Restriction Rules

These rules define the population boundaries to minimize risk in susceptible individuals, focusing on exclusions based on physiological state and organ function.

Interactions with other medicines and products

The interaction profile of rosuvastatin (Crestor) is officially documented by regulatory agencies and focuses on minimizing changes in drug exposure and the additive risk of skeletal muscle effects.

Restrictions and Critical Combinations

Co-administration with Cyclosporine leads to significantly increased rosuvastatin exposure, mandating a maximum dose restriction. The combination of rosuvastatin and Gemfibrozil should be avoided due to the documented increase in exposure and heightened risk of muscle-related toxicity; a maximum rosuvastatin dose limitation applies if co-administration is necessary.

Certain Antiviral Agents (e.g., specific regimens for HIV and HCV) are also documented to increase rosuvastatin plasma levels through transporter inhibition, requiring dose restrictions or the combination to be not recommended.

Population-Specific Notes

Specific patient populations, including those of Asian descent and those with severe renal impairment, have officially documented higher systemic exposure to rosuvastatin, a factor that must be considered when co-administering interacting medicines.

The mechanism initiates with the competitive inhibition of the key enzyme, HMG-CoA Reductase, which is the rate-limiting enzyme in the liver's Mevalonate Pathway. By slowing the body's synthesis of cholesterol, this action fundamentally alters the metabolic equilibrium of cholesterol in the liver, which acts as the trigger for the subsequent steps. The resulting drop in internal cholesterol forces the hepatocyte to compensate by rapidly increasing the expression of Low-Density Lipoprotein ( LDL) Receptors on its surface. This compensatory mechanism increases the liver's catabolism of circulating LDL-C from the bloodstream, leading to a decrease in these lipoproteins in plasma. Rosuvastatin also affects the synthesis of non-sterol intermediates within the mevalonate pathway, which are crucial for cellular signaling. This secondary, or pleiotropic, effect is associated with the modulation of inflammation markers like C-reactive protein ( CRP) and affects endothelial function within the vascular system.

How to Use CRESTOR (Rosuvastatin): Official Administration Guidelines

CRESTOR is an oral medication that must be taken once daily as directed by a healthcare provider. The patient must be placed on a standard cholesterol-lowering diet before starting treatment and must continue this diet during therapy.

Administration Details

Dosing for Adult Patients

For adults, the dosage range is 5 mg to 40 mg once daily.

• Initial Dose (General): Typically starts at 10 mg or 20 mg once daily, adjusted every four weeks based on lipid levels and patient response.
• Maximum Dose (General): The 40 mg dose is reserved only for patients who have not achieved their treatment goal with the 20 mg dose.
• Special Considerations: A starting dose of 5 mg is recommended for patients over 70 years of age, those with severe renal impairment (not on hemodialysis), or patients of Asian ancestry. The dosage must be limited when taken with certain other medications, such as cyclosporine (limited to 5 mg once daily) or lopinavir/ritonavir (limited to 10 mg once daily).

Research Evidence / Overview of studies for Крестор (Rosuvastatin)

The research landscape for Крестор (rosuvastatin) is based primarily on evidence from Randomized Controlled Trials (RCTs) and large-scale, long-term studies. This evidence contributes to the broader understanding of rosuvastatin’s evaluation in managing blood lipids and exploring cardiovascular risk patterns.

Research Evidence for Managing Cholesterol and Lipids

Research examining rosuvastatin in patient populations with elevated blood fats (hypercholesterolemia and mixed dyslipidemia) typically involves RCTs lasting from a few weeks up to several months. These studies monitored biomarkers—measurable substances in the blood—like "bad" cholesterol (LDL-C) and "good" cholesterol (HDL-C). The primary goal of these short-term studies was to monitor how these lipid levels were reported to shift during the study period.

Findings describe patterns observed in the studies related to changes in lipid levels for patients taking the study drug. Comparative research examined observed changes against other similar medications (statins). Reports noted that these measured shifts in lipid biomarkers were typically established within the relatively short follow-up durations of 8 to 12 weeks.

Studies in Children and Adolescents (Special Populations)

Studies have explored rosuvastatin in children and adolescents, sometimes as young as 7 to 10 years old, who have been diagnosed with Heterozygous Familial Hypercholesterolemia (HeFH). The research examined changes in their lipid biomarkers, similar to the adult studies. Results apply only to the populations studied, meaning the findings are specific to this group of patients with inherited high cholesterol.

Research Evidence for Reducing the Risk of Heart Attack and Stroke

Research has explored patterns related to rosuvastatin and outcomes reflecting cardiovascular function such as the occurrence of heart attack and stroke using large, long-term RCTs that monitored patients over many years. These studies specifically tracked the occurrence of Major Adverse Cardiovascular Events (MACE)—a composite endpoint that includes nonfatal heart attack, nonfatal stroke, and cardiovascular death. Researchers explored populations with established heart disease (secondary prevention) and those with multiple risk factors (primary prevention).

Key Limitations and Remaining Research Questions

Early trials primarily used surrogate outcomes (biomarkers) to track short-term changes, meaning they did not directly measure long-term clinical events. In terms of clinical event trials, some key studies were stopped before their original planned end date. This means that while the trials completed their intended primary analyses, there is limited information for long-term outcomes regarding the collection of data on very rare events or fully characterizing long-term observation patterns.

Key Studies & References Statins: Actions and Administration - NIH StatPearls (Overview of Statin Class Evidence)

Common questions about Крестор (FAQ)

Q: What is the recommended way to store this medication?

Official regulatory documents indicate that this medication should be kept in a closed container at room temperature. It is important to protect the tablets from excessive heat, moisture, and direct light. The medication should not be frozen.

Q: Can I drink alcohol while taking this medicine?

Regulatory information advises that excessive alcohol consumption (either frequent heavy drinking or short-term binge drinking) should be avoided while taking this medicine. This precaution is noted because excessive alcohol intake may increase the risk of a rare but serious side effect called lactic acidosis.

Q: Does taking this medicine cause sleepiness or drowsiness?

While regulatory documents do not list common side effects as simple 'sleepiness' or 'drowsiness,' a symptom called somnolence (a state of strong desire for sleep) is mentioned. This symptom is associated with the rare but serious condition, lactic acidosis. If an individual experiences unexpected drowsiness, it is recommended to monitor for other potential concerning symptoms.

Q: Can children 2 years old use this medicine?

According to the official product information, this medicine is indicated for treating type 2 diabetes in children starting at 10 years of age. Therefore, it is not approved for use in children who are two years old.

How to Store and Dispose of Crestor (Rosuvastatin)

Crestor tablets must be stored according to specific conditions defined by regulatory labeling to maintain stability.

Storage Requirements

Disposal Instructions

Regulatory instructions advise that unused or expired Crestor must not be disposed of in household waste or flushed down the toilet (wastewater). Disposal should be done by consulting a pharmacist, as these methods help to protect the environment.